The ONCOVALUE consortium partners aim to develop novel AI-based tools to automate the collection and analytics of clinical data. This pioneering work will enable a new approach to the utilization of real world-data in cancer treatment.
“Siemens Healthineers actively works with AI supported innovations that drive greater efficiency and highly effective patient outcomes in cancer care at every step of the way – from the first appointment to treatment planning and delivery and to follow-up care. We are proud to be part of this EU funded pioneering work in a consortium formed by several leading European cancer hospitals and industry partners.”
Corporate Account Executive, Siemens Healthineers Finland
ONCOVALUE project aims to increase the capabilities of European cancer hospitals to easily and timely collect real-world data (RWD). Systematic collection and analysis of clinical data is needed for the continuous development of treatment and improvement of outcomes. Real-time high-quality clinical data also supports the decision making of regulatory and HTA bodies on the value of novel cancer therapies. At its best ONCOVALUE project may also enhance the commissioning of effective novel therapies.
Additionally, an end-to-end infrastructure for RWD reporting in health regulatory and HTA decision-making will be built with potential to lead to safer, more efficient, and affordable therapies, technologies, and digital solutions for personalized cancer care. Furthermore, ONCOVALUE will ensure the implementation of the developed guidelines and methodologies by providing trainings.
More information on HUS website
In English
Insights into oncology
The current series of Insights Series papers focus on oncology, presents strategies and looks at ideas how cancer care can be improved in the future to realize the vision of a world without fear of cancer.
Contact
Ossi Koskinen, tel +358 50 433 7560
Send email